Depression therapy: Future prospects

Abstract

Current biological approaches to the treatment of depression focus mainly on modification of monoaminergic neurotransmission. New agents targeting these neurotransmitters are under development. Many novel antidepressant targets are however under investigation. These include the neurokinins, glutamate, purinoceptors, opioids and trophic factors. While many of these potential targets are likely to fail clinical development, exciting novel therapeutic options are likely to emerge.

• Depression Glutamate Receptors Opioids Dopamine Neurokinins Purinoceptors Neurotrophins Serotonin